Tasly Group

Tasly Group is a prominent Chinese healthcare conglomerate primarily focused on the modernization of Traditional Chinese Medicine (TCM). Established in 1994 and headquartered in Tianjin, the company has built a diverse portfolio spanning cardiovascular, oncology, and metabolic diseases. Its flagship product, Compound Danshen Dripping Pills (T89), is a landmark in TCM globalization, having reached Phase 3 clinical trials in the United States. Beyond TCM, Tasly has significantly expanded into biologics and chemical drugs through its subsidiaries, maintaining a robust R&D pipeline and large-scale GMP manufacturing facilities. The group operates a vertically integrated model from herbal cultivation to global pharmaceutical distribution.